🇺🇸 Pemetrexed + cisplatin in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 10
Most-reported reactions
- Death — 1 report (10%)
- Gait Inability — 1 report (10%)
- Hemiparesis — 1 report (10%)
- Malignant Neoplasm Progression — 1 report (10%)
- Metastases To Bone — 1 report (10%)
- Metastases To Central Nervous System — 1 report (10%)
- Metastases To Heart — 1 report (10%)
- Metastases To Liver — 1 report (10%)
- Metastases To Lung — 1 report (10%)
- Metastases To Pleura — 1 report (10%)
Other Oncology approved in United States
Frequently asked questions
Is Pemetrexed + cisplatin approved in United States?
Pemetrexed + cisplatin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pemetrexed + cisplatin in United States?
AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.